1
ALL1
Sprout PharmaYear
1
ALL1
2022DEALS // DEV.
1
ALL1
DevelopmentsCountry
1
ALL1
U.S.A1
ALL1
Not ApplicableTherapeutic Area
1
ALL1
Psychiatry/PsychologyStudy Phase
1
ALL1
ApprovedDeal Type
0
ALLProduct Type
1
ALL1
Small moleculeDosage Form
1
ALL1
PillLead Product
1
ALL1
FlibanserinTarget
1
ALL1
5-HT1A receptorLead Product(s) : Flibanserin
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : The baseline means Female Sexual Function Index (FSFI) score was 13.3, with FSFI- desire score of 1.96 after 8 weeks on Addyi (flibanserin), an FDA-approved non-hormonal pill mean FSFI total score increased to 19.4, and the mean FSFI-d score increased to...
Product Name : Addyi
Product Type : Small molecule
Upfront Cash : Not Applicable
March 15, 2022
Lead Product(s) : Flibanserin
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable